Cargando…
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
Comparisons of duration of response (DoR) and duration of clinical benefit (DoCB) within clinical trials are prone to biases. To address these biases, we used new methodology to prospectively analyze expected DoR and expected DoCB. Objective response rate and clinical benefit rate were calculated fo...
Autores principales: | Garnett, Sally Anne, Martin, Miguel, Jerusalem, Guy, Petruzelka, Lubos, Torres, Roberto, Bondarenko, Igor N., Khasanov, Rustem, Verhoeven, Didier, Pedrini, José L., Smirnova, Iva, Lichinitser, Mikhail R., Pendergrass, Kelly, Lindemann, Justin P. O., Di Leo, Angelo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586113/ https://www.ncbi.nlm.nih.gov/pubmed/23378064 http://dx.doi.org/10.1007/s10549-012-2395-8 |
Ejemplares similares
-
Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial
por: Leo, Angelo Di, et al.
Publicado: (2013) -
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis
por: Bachelot, Thomas, et al.
Publicado: (2013) -
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
por: Watanabe, Kenichi, et al.
Publicado: (2023) -
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017) -
Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)